In this study, researchers treated 37 basal cell carcinoma (BCC) lesions from 30 patients, with follow-ups at 5 time points after baseline examination.
A novel nonthermal bioelectric treatment modality was indicated safe and effective for use among individuals who have low-risk nodular and superficial basal cell carcinoma (BCC) lesions, according to recent study findings appearing in Frontiers in Oncology.
Outcomes were evaluated among 30 patients who presented with 37 BCC lesions in an ongoing study. They were evaluated at baseline and then 3, 7, 14, 30, and 60 days following treatment with the CellFX system, a method of Nano-Pulse Stimulation using “a new, nonthermal bioelectric modality that applies ultrashort pulses of electric energy to trigger regulated cell death (RCD) in treated tissues and that permeabilizes intracellular organelles to activate the cell’s own self-destruct pathway of programmed or regulated cell death,” the authors wrote. An additional advantage of the method is that surrounding tissue and cells, compared with outcomes from cryotherapeutic procedures, are preserved.
Follow-up during the 5 initial visits was via photographs and histological exam, and then after excision, additional follow-ups were conducted at 14, 30, and 60 days. Fifty-three percent of the study population were female patients, and their mean (range) age was 65 (37-81) years; 97% were White patients, and 3% were American Indian patients.
Among the overall cohort, Mohs surgery was the most common treatment modality in 75%, followed by surgical excision in 63%, curettage and electrodesiccation in 25%, and topical 5-fluorouracil and cryosurgery in 8% each. Eighty-four percent of the BCC lesions had a nodular component, the study authors noted, with 68% being purely nodular and the remaining 16%, superficial and nodular.
To guide the CellFX treatment tip—microneedle skin surface application—1 of 4 clear plastic templates were applied to the skin and 4 tattoo dots marked the treatment zone. Tip treatment size breaks down as follows:
Overall, complete histological clearance was seen for 92% of the 37 BCC lesions. In addition, all of the patients treated with the 5-x-5 mm tip and 97% treated with the with 5-x-5 mm and 10-x-10 mm tips saw histological clearance.
No serious adverse events or complications occurred. At 60 days post treatment with CellFX, the most common skin effects were scarring (84% vs 38% at baseline), erythema (68% vs 95%, respectively), hyperpigmentation (27%), and scaling (22%). The authors noted that their comparison of the scarring with photos from the pretreatment biopsy indicate “most scars may have been caused by the pretreatment biopsy rather than CellFX treatment,” and physician evaluation indicated the area treated with CellFX was less likely to scar.
With 3 lesions exhibiting residual BCC, the authors noted that progress can be made by improving the guides for tip placement and investigating different energy levels for the CellFX treatment.
“We conclude that the CellFX System is safe and effective for the treatment of low-risk nodular and superficial BCC,” the authors concluded, “and may be an emerging, nonsurgical treatment option for the treatment of primary BCCs requiring maximal sparing of tissues, including facial lesions.”
Reference
Ross AS, Schlesinger T, Harmon CB, et al. Multicenter, prospective feasibility study of Nano-Pulse Stimulation technology for the treatment of both nodular and superficial low-risk basal cell carcinoma. Front Oncol. Published online December 2, 2022. doi:10.3389/fonc.2022.1044694
Emily Goldberg Shares Insights as a Genetic Counselor for Breast Cancer Risk Screening
October 30th 2023On this episode of Managed Care Cast, Emily Goldberg, MS, CGC, a genetic counselor at JScreen, breaks down how genetic screening for breast cancer works and why it is so important to increase awareness and education around these screening tools available to patients who may be at risk for cancer.
Listen
Patients With Advanced, Recurrent Melanoma May Experience Lasting AEs From ICM Therapy
May 9th 2024A cross-sectional, mixed-methods study found that adverse effects (AEs) can occur even after 1 year of treatment with immune checkpoint modulator (ICM) therapy in patients with melanoma.
Read More
Examining Telehealth Uptake to Increase Equitable Care Access
January 26th 2023To mark the publication of The American Journal of Managed Care®’s 12th annual health IT issue, on this episode of Managed Care Cast, we speak with Christopher M. Whaley, PhD, health care economist at the RAND Corporation, who focuses on health economics issues, including the influence of the COVID-19 pandemic on health care delivery.
Listen
Bringing Connectivity to the Specialty Pharmacy Workflow
May 2nd 2024In a session during the final full day of conference activity at AXS24, experts from CVS Health and Surescripts emphasized the need to simplify the prescribing workflow for specialty medication through proactive messaging, automation, and interoperability.
Read More